(24/7 MARKET NEWS) – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that it had a meeting and a written response from the FDA last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals is trading at $1.23, 2-cents lower (-1.60%), on volume of 910 thousand shares traded.
Its 52-week range is $ 0.4899 to $3.87. Its next key inflection points are $1.41, $1.53, and this morning’s premarket high of $1.68. If can break through the $1.68 resistance level, on strong volume, it could try to challenge its February trading levels.
View original content: https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-provides-progress-update-on-interactions-with-the-fda-regarding-path-to-nda-submission-for-nrx-101-301725517.html
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.